Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
PLUS THERAPEUTICS, Inc. (PSTV)
Company Research
Source: GlobeNewswire
HOUSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces its participation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting, Melanoma Research Foundation (MRF) Brain Metastases Summit 4.0 on November 9, 2025 in Alexandria, VA. Dr. Andrew Brenner, M.D., Ph.D., Professor of Medicine in the Division of Hematology and Oncology at The University of Texas Health Science Center at San Antonio will highlight the Company’s REYOBIQ and ReSPECT-LM clinical trial results in the session on leptomeningeal metastases (LM) disease. Recall, at the 2025 SNO/ASCO CNS Metastases conference in August, ReSPECT-LM Phase 1 single dose escalation trial data showed: REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measuresRNA sequencing and
Show less
Read more
Impact Snapshot
Event Time:
PSTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSTV alerts
High impacting PLUS THERAPEUTICS, Inc. news events
Weekly update
A roundup of the hottest topics
PSTV
News
- Plus Therapeutics Announces Pricing of Upsized $15 Million Public OfferingGlobeNewswire
- Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases [Yahoo! Finance]Yahoo! Finance
- Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal MetastasesGlobeNewswire
- Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
PSTV
Earnings
- 8/14/25 - Beat
PSTV
Sec Filings
- 1/16/26 - Form 8-K
- 1/14/26 - Form 424B4
- 1/14/26 - Form EFFECT
- PSTV's page on the SEC website